Pacira BioSciences (NASDAQ:PCRX) Issues Earnings Results, Beats Estimates By $0.08 EPS

Pacira BioSciences (NASDAQ:PCRX) announced its quarterly earnings results on Tuesday. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.08, FiscalAI reports. The business had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 earnings per share.

Here are the key takeaways from Pacira BioSciences’ conference call:

• Second-quarter revenue increased 6% to $192.4 million, led by EXPAREL sales growth of 3% to $147.8 million, ZILRETTA growth of 4%, and iovera° growth of 21%.
• EXPAREL continued gaining share despite softness in deferrable elective soft-tissue procedures. Expanded commercial-payer coverage, including UnitedHealthcare, brings separate reimbursement to more than 150 million covered lives, supporting further adoption in outpatient settings.
• Pacira lowered its 2026 total revenue guidance to $735 million-$760 million from $745 million-$770 million, primarily reflecting the iovera° divestiture; consolidated non-GAAP gross margin also declined to 78% from 82% a year ago.
• The company expects several pipeline catalysts by year-end, including data from ZILRETTA’s shoulder osteoarthritis study, iovera°’s spasticity study, and Part A of the PCRX-201 Phase II trial. Pacira also reported $251 million in cash and investments before receiving the $70 million upfront payment from Zimmer Biomet.
• Pacira completed the iovera° divestiture to Zimmer Biomet for up to $140 million, filed EXPAREL for approval in South Korea through LG Chem with potential revenue beginning in 2027, and said it remains open to additional partnerships while focusing capital on near-term, risk-managed growth opportunities.

Pacira BioSciences Stock Down 9.2%

Pacira BioSciences stock traded down $2.55 during midday trading on Wednesday, hitting $25.07. 469,203 shares of the stock were exchanged, compared to its average volume of 688,468. Pacira BioSciences has a 52-week low of $18.80 and a 52-week high of $27.66. The company has a quick ratio of 3.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.56. The business’s 50-day moving average price is $24.60 and its 200-day moving average price is $23.32. The stock has a market capitalization of $986.50 million, a price-to-earnings ratio of 209.10 and a beta of 0.27.

Insider Activity at Pacira BioSciences

In other news, SVP Lauren Riker sold 6,115 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total value of $143,702.50. Following the transaction, the senior vice president owned 62,284 shares in the company, valued at $1,463,674. The trade was a 8.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PCRX. Dimensional Fund Advisors LP boosted its holdings in shares of Pacira BioSciences by 0.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company’s stock worth $55,751,000 after buying an additional 11,831 shares during the last quarter. Balyasny Asset Management L.P. raised its position in Pacira BioSciences by 36.1% in the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock worth $50,925,000 after acquiring an additional 565,288 shares during the period. Goldman Sachs Group Inc. boosted its stake in Pacira BioSciences by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after acquiring an additional 367,869 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Pacira BioSciences by 7.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 676,352 shares of the company’s stock valued at $17,504,000 after acquiring an additional 49,079 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Pacira BioSciences by 7.9% during the 3rd quarter. Invesco Ltd. now owns 517,424 shares of the company’s stock valued at $13,334,000 after acquiring an additional 38,025 shares during the period. Institutional investors own 99.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PCRX shares. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Pacira BioSciences in a report on Wednesday, July 1st. Weiss Ratings upgraded shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, May 20th. Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank Of Canada lifted their price objective on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a report on Friday, May 1st. Finally, Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $29.60.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.